Challenging Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Program Overview

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Credit Expired

0.25 CE Credit(s)

Expires: November 23, 2022

Target Audience

This activity is intended for pulmonology and infectious disease clinicians who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Faculty

Julie V. Philley, MD

Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD

Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C

Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Privacy | Terms of Use